AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie synthroid (levothyroxine) [legacy through FY21] — Worldwide reported growth YoY (%) (%)
Form 8-K Key Product Revenues Schedule
Latest, Q4 2021
0.9%
Period ended Dec 31, 2021
Change on a year earlier
+6.0 pts
-5.1% in Q4 2020
History
7 quarters
Since Q2 2020
Sources
7
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Synthroid (levothyroxine) [legacy through FY21] — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2021 | Dec 31, 2021 | 0.9% | +6.0 pts | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| Q3 2021 | Sep 30, 2021 | -0.8% | +2.8 pts | Form 8-K (abbv-20210930xexhibit991.htm, filed 2021-10-29) ↗ |
| Q2 2021 | Jun 30, 2021 | 5.0% | +14.7 pts | Form 8-K (abbv-20210630xexhibit991.htm, filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | -6.8% | – | Form 8-K (abbv-20210331xexhibit991.htm, filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | -5.1% | – | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| Q3 2020 | Sep 30, 2020 | -3.6% | – | Form 8-K (abbv-20200930xex991.htm, filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | -9.7% | – | Form 8-K (abbv-20200630xexhibit991.htm, filed 2020-07-31) ↗ |
Cite this data
StockData. (2026). AbbVie Synthroid (levothyroxine) [legacy through FY21] — Worldwide reported growth YoY (%) (%), quarterly Q2 2020–Q4 2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/synthroid_ww_rep_yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.